Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
By Marie Vetizou, J. Pitt, Romain Daillère, P. Lepage, N. Waldschmitt, C. Flament, S. Rusakiewicz, B. Routy, M. Roberti, Connie P. M. Duong and 28 more. Science, 2015
3,116 citations recorded by the source corpus.
Gut microbes affect immunotherapy The unleashing of antitumor T cell responses has ushered in a new era of cancer treatment. Although these therapies can cause dramatic tumor regressions in some patients, many patients inexplicably see no benefit. Mice have been used in two studies to investigate what might be happening. Specific members of the gut microbiota influence the efficacy of this type of immunotherapy (see the Perspective by Snyder et al.). Vétizou et al. found that optimal responses to anticytotoxic T lymphocyte antigen blockade required specific Bacteroides spp. Similarly, Sivan et al. discovered that Bifidobacterium spp. enhanced the efficacy of antiprogrammed cell death ligand 1 therapy. Science, this issue, p. 1079 and p. 1084; see also p. 1031 Gut microbes modulate the effectiveness of cancer immunotherapies in mice. Antibodies targeting CTLA-4 have been successfully used as cancer immunotherapy. We find that the antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species. In mice and patients, T cell responses specific for B. thetaiotaomicron or B. fragilis were associated with the efficacy of CTLA-4 blockade. Tumors in antibiotic-treated or germ-free mice did not respond to CTLA blockade. This defect was overcome by gavage with B. fragilis, by immunization with B. fragilis polysaccharides, or by adoptive transfer of B. fragilis–specific T cells. Fecal microbial transplantation from humans to mice confirmed that treatment of melanoma patients with antibodies against CTLA-4 favored the outgrowth of B. fragilis with anticancer properties. This study reveals a key role for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade.
Subfields: Biological Psychiatry, Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/8332dd6438dcdd3f68c465b8754fa88560a635f5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biological Psychiatry
In Infectious Diseases
In Molecular Biology
- Curtis Huttenhower
- Dirk Gevers
- W. Garrett
- Rob Knight
- Y. Belkaid
- Eric G. Pamer
- L. Zitvogel
- J. Petrosino
Citations in the corpus
- Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. (2016, methodology): “To analyze the role of NOD2 receptors expressed by intestinal epithelial cells (IECs), we reduced the model system to cryptderived 3D-small intestine enteroids generated from intestinal stem cells harvested from WT versus Nod2 / mice (Vétizou et al., 2015).”
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors (2018, background): “Finally, potential molecular mimicry between gut microbiota and tumor might participates in tumor-specific immune response [92].”
- Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients (2017, background): “Our findings of distinct gut microbes associated with human ICT response for IN and P are unique and consistent with results in preclinical models [9,10].”
- Gut microbiota modulation of chemotherapy efficacy and toxicity (2017, neutral): “Conversely, to date, no trials have examined whether antibiotics might preferentially improve chemotherapy efficacy, and such approaches have largely been used as a method for experimental modulation of microbiota–host drug interactions 26,29 .”
- Cellular Senescence: Aging, Cancer, and Injury. (2019, background): “Moreover, increasing evidence shows that the microbiota is important for the efficacy of both classical chemotherapy (328) and of immune checkpoint inhibitors (anti–PD-L1, anti–CTLA-4, and anti-PD1) (298, 327).”
- The microbiome and cancer (2018, background): “The Zitvogel study [87] was motivated by the observation that patients treated with anti-CTLA4 develop antibodies against gut flora.”
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance (2017, background): “Studies have also begun to uncover mechanisms of resistance, including expression of immune checkpoint molecules (10, 14–21), insufficient infiltration of CD8 T cells (9, 10), oncogenic pathways (22–24), transcriptomic resistance signatures (25), lack of sensitivity to interferon (IFN) signaling (26”
- The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. (2018, background): “Important initial insights came from murine models (Sivan et al., 2015; Vetizou et al., 2015), and many of these findings have now been validated in patient cohorts treated with immunotherapy, specifically immune checkpoint blockade.”